WO2014083575A2 - Improved process for the preparation of boceprevir intermediate - Google Patents
Improved process for the preparation of boceprevir intermediate Download PDFInfo
- Publication number
- WO2014083575A2 WO2014083575A2 PCT/IN2013/000697 IN2013000697W WO2014083575A2 WO 2014083575 A2 WO2014083575 A2 WO 2014083575A2 IN 2013000697 W IN2013000697 W IN 2013000697W WO 2014083575 A2 WO2014083575 A2 WO 2014083575A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- process according
- acid
- give
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- MFBZMDIQWYXOSP-CIUDSAMLSA-N (1r,2s,5s)-6,6-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid Chemical compound OC(=O)[C@H]1N(C(=O)OC(C)(C)C)C[C@@H]2C(C)(C)[C@H]12 MFBZMDIQWYXOSP-CIUDSAMLSA-N 0.000 title description 2
- 239000002253 acid Substances 0.000 claims abstract description 20
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims abstract description 9
- 229960000517 boceprevir Drugs 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 62
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 claims description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229940086542 triethylamine Drugs 0.000 claims description 7
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 5
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- ODHXBMXNKOYIBV-UHFFFAOYSA-N triphenylamine Chemical compound C1=CC=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 ODHXBMXNKOYIBV-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 26
- 150000003839 salts Chemical class 0.000 abstract description 11
- UTALHROEBHXMFG-UHFFFAOYSA-N 3-amino-4-cyclobutyl-2-hydroxybutanamide Chemical compound NC(=O)C(O)C(N)CC1CCC1 UTALHROEBHXMFG-UHFFFAOYSA-N 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 32
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- -1 bertzylideneamine Chemical compound 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 231100001261 hazardous Toxicity 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 229910000000 metal hydroxide Inorganic materials 0.000 description 4
- 150000004692 metal hydroxides Chemical group 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- SJVGFKBLUYAEOK-SFHVURJKSA-N 6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile Chemical compound FC=1C=C(C=C(C=1)F)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N SJVGFKBLUYAEOK-SFHVURJKSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 2
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- QUGJYNGNUBHTNS-UHFFFAOYSA-N ethyl 2-(benzhydrylideneamino)acetate Chemical compound C=1C=CC=CC=1C(=NCC(=O)OCC)C1=CC=CC=C1 QUGJYNGNUBHTNS-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- DRDVJQOGFWAVLH-UHFFFAOYSA-N tert-butyl n-hydroxycarbamate Chemical compound CC(C)(C)OC(=O)NO DRDVJQOGFWAVLH-UHFFFAOYSA-N 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- 229940086210 victrelis Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Definitions
- the present invention relates to the process for the preparation of 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof and its further conversion into Boceprevir.
- Boceprevir (lR,5S)-N-[3-Amino-l-(cyclobutyImethyI)-2,3-dioxopropyl]-3-[2(S)- [[[(l,l-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3- azabicyclo [3.1.0]hexan-2(S)-carboxamide, having formula I is a hepatitis C virus ("HCV”) protease inhibitor, developed by Merck & Co and marketed under the brand name of VICTRELIS.
- HCV hepatitis C virus
- the processes exemplified above employ hazardous reagents and are difficult to handle in an industrial scale. There is a need in the art to provide a process which is not hazardous, cost effective with enhanced purity and yields.
- the present invention provides a commercially viable and easy to handle process with simple reagents and with enhanced purity and yield of intermediate I or an acid addition salt thereof.
- the principle object of the present invention is to provide an improved process for preparing 3-amino-3-cyclobutylmethyl-2-hydroxypropiffnide of Intermediate I or an acid addition salt thereof.
- Another object of the present inv e a novel intermediate of formula E.
- the present invention provides a process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide of Intermediate I or an acid addition salt thereof comprising the steps of:
- the present invention provides an improved process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof of Intermediate I. It also provides a novel intermediate of formula E.
- R- alkyl group L-Leaving group ; P-Protecting group
- R- refers to an alkyl group straight or branched CI -9 alkyl, includes methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, s-butyl, t-butyl.
- L refers to a leaving groups known in the art includes, halides, sulphoriate groups such as alkylsulphonates arylsulphonates.
- P refers a protecting group known in the art includes Di t-Butyl dicarbamate (Boc), Benzyl carbamate, acetamide, trifluoroacetamide, phthalimide, benzylchloride, benzoylchloride, tritylamine, bertzylideneamine, tosylamide, methoxyethxoxymethyl, tetrahydropyaranyl (THP), and tertiary butyl.
- Di t-Butyl dicarbamate Boc
- Benzyl carbamate Benzyl carbamate
- acetamide trifluoroacetamide
- phthalimide benzylchloride
- benzoylchloride benzoylchloride
- tritylamine bertzylideneamine
- tosylamide methoxyethxoxymethyl
- THP tetrahydropyaranyl
- Halide refers to F, CI, Br and I.
- the present invention provides a process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof of Intermediate I comp ising the steps of: a) A with compound of
- R- alkyl group L-Leaving group; P-Protecting group.
- a benzophenone imine compound of formula A is reacted with cyclobutyl methyl derivative of formula B to give amine compound of formula C in the presence of a suitable base and solvent.
- the suitable base is selected from metal hydroxide includes potassium hydroxide (KOH), sodium hydroxide (NaOH), metal carbonate includes sodium carbonate and potassium carbonate, preferably metal hydroxide potassium hydroxide;
- the suitable solvent is selected from polar aprotic solvent such as dimethyl sulfoxide ⁇ (DMSO), dimethylacetamide, tetrahydrofuran (THF), acetone, dimethyl formamide (DMF) and acetonitrile; preferably DMSO.
- DMSO dimethyl sulfoxide ⁇
- THF tetrahydrofuran
- acetone dimethyl formamide
- acetonitrile preferably DMSO.
- the reaction between compound of formula A and cyclobutyl methyl derivative of formula B can optionally be carried out in presence of a phase transfer catalyst such as tetrabutyl ammonium bromide (TBAB) and crown ethers to give amine compound of formula C.
- TBAB tetrabuty
- the amine compound of formula C is protected with protecting group P by treating with a protecting agent in a suitable solvent includes hexane, diethyl ether and methylene chloride (MDC), preferably methylene chloride.
- a protecting agent in a suitable solvent includes hexane, diethyl ether and methylene chloride (MDC), preferably methylene chloride.
- MDC methylene chloride
- the amine protected compound of formula C is hydrolysed to obtain formula D by treating with a base and suitable solvent, wherein the suitable base is selected from alkaline metal hydroxide, preferably NaOH in a suitable solvent selected from polar solvents such as methanol, ethanol, isopropyl alcohol (IP A) and propanol, arid butanol, preferably ethanol.
- the acid compound of formula D is converted into a morpholine amide of formula E by treating formula D with a morpholine in presence of a suitable solvent and coupling agent.
- the suitable solvent includes methylene chloride (MDC), toluene, xylene and carbon tetrachloride (CC1 4 ), preferably methylene chloride.
- the suitable coupling agent includes l-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride (EDC.HC1), ⁇ , ⁇ '-Dicyclohexylcarbodiimide (DCC), 1,1 * - Carbonyldiimidazole (CDI).
- EDC.HC1 l-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride
- DCC ⁇ , ⁇ '-Dicyclohexylcarbodiimide
- CDI 1,1 * - Carbonyldiimidazole
- Compound of formula E can also be prepared by reacting alkylchloroformates such as ethylchloroformate, isobutylchloroformate with a compound of formula D followed by a morpholine.
- compound of formula E can also be prepared directly from amino protected compound of formula C by reacting with a morpholine.
- formula E is also prepared by converting
- the morpholine amide compound of formula E is reduced into aldehyde compound of formula F by treating formula E with suitable reducing agent and suitable solvent, wherein the suitable reducing agent includes lithium aluminium hydride (LAH), diisobutylaluminum hydride (DIBAL-H) and sodium bis(2-methoxyethoxy) aluminumhydride (vitride).
- suitable reducing agent includes lithium aluminium hydride (LAH), diisobutylaluminum hydride (DIBAL-H) and sodium bis(2-methoxyethoxy) aluminumhydride (vitride).
- the suitable solvent includes ether solvents such as toluene, tetrahydrofuran (THF), diethyl ether.
- the present invention provides a novel and simple process by replacing compound of formula J with the morpholine amide of formula E and further it is successfully established the reduction of compound of Formula J into corresponding aldehyde in process of preparing Intermediate I by employing commercially feasible reagent such as vitride solution instead of hazardous metallic hydride such as Lithium aluminium hydride.
- the aldehyde compound of formula F is reacted with a cyanohydrin compound in presence of a suitable base and suitable solvent such as toluene, dichloromethane to obtain cyano compound of formula G.
- the cyanohydrin compound for the reaction is selected from ketone cyanohydrin, preferably acetone cyanohydrin.
- the base is selected from diisopropyl ethyl amine, dimethylamine, triethyl amine (TEA), trirnethyl amine, methylamine, ethanolamme, triphenylamine, pyridine and piperidine, preferably TEA.
- the cyanohydrin compound of formula G is hydrolyzed with a base in a suitable solvent such as DMSO and in presence H 2 0 2 to obtain amide compound of formula H, wherein the base is selected from potassium carbonate, sodium carbonate, preferably potassium carbonate.
- the cyanohydrin compound of formula G is converted into Intermediate I of ah acid addition salt thereof as per the process disclosed in US 20050249702 depicted in scheme 3,
- the amide compound of formula H is deprotected by treating with an acid in suitable solvent to give Intermediate I or an acid addition salt thereof
- the acid is selected from hydrochloric acid (HQ), hydrobromic acid (HBr), sulfuric acid (H 2 S04), trifluoro acetic acid (TFA), phosphoric acid (H 3 PO 4 ), paratoluene sulfonic acid (pTSA) and the like, preferably HCl.
- the suitable solvent is selected from polar solvents such as methanol, ethanol, n-propanol, isopropyl alcohol (IPA) and butanol preferably IPA.
- present invention provides an improved process for preparing an aldehyde compound of formula F by reducing compound of formula J as represented in scheme 5.
- the reduction of the compound of formula J into compound of formula F is carried out by treating compound of formula J with sodium bis(2-methoxyethoxy)alumirtumhydride (Vitride) in a suitable solvent selected from polar aprotic solvent includes, tetrahydrofurari (THF); preferably THF.
- a suitable solvent selected from polar aprotic solvent includes, tetrahydrofurari (THF); preferably THF.
- the present invention provides novel intermediate of formula E.
- the novel morphoiine compound of formula E is converted into Boceprevir of formula I.
- the aldehyde compound of formula J is further converted into Boceprevir by the conventional methods.
- the Intermediate I is converted into Boceprevir of formula I as per the process disclosed in US 7012066, US 20050249702, WO 2008079216 and WO2002008244.
- N-diphenylmethyleneglycine ethyl ester (17.9 g, Example 1) was dissolved in 50 ml of DMSO and cooled to 0 °C. To this 11.27 g of potassium hydroxide was added and stirred for 10 min. To the reaction mixture 10 g of Cyclobutyl methyl bromide (Formula B-Leaving group is halide, preferably Br) was added at 0 °C and continued stirring for one hour at 0 °C. After completion of the reaction, toluene was added to the reaction mass and filtered through Hyflo bed. Water was added to the filtrate and extracted with toluene.
- Formula B-Leaving group is halide, preferably Br
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the process for the preparation of 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof and its further conversion into Boceprevir.
Description
IMPROVED PROCESS FOR THE PREPARATION OF BOCEPREVIR INTERMEDIATE
FIELD OF INVENTION
The present invention relates to the process for the preparation of 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof and its further conversion into Boceprevir. BACKGROUND OF THE INVENTION
Boceprevir, (lR,5S)-N-[3-Amino-l-(cyclobutyImethyI)-2,3-dioxopropyl]-3-[2(S)- [[[(l,l-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3- azabicyclo [3.1.0]hexan-2(S)-carboxamide, having formula I is a hepatitis C virus ("HCV") protease inhibitor, developed by Merck & Co and marketed under the brand name of VICTRELIS.
Inter mediate I
US patent 6992220 claims a process for the synthesis of Intermediate I and is represented in below scheme 1.
VII
VI
Scheme 1
VIII
US 2011034705 disclose that the process described in US 6992220 ends with low yield of Intermediate I from the various intermediates described therein.
US 201 1034705 describe a process for preparing Intermediate I and is represented as shown in Scheme 2.
ij
The processes exemplified above employ hazardous reagents and are difficult to handle in an industrial scale. There is a need in the art to provide a process which is not hazardous, cost effective with enhanced purity and yields. The present invention provides a commercially viable and easy to handle process with simple reagents and with enhanced purity and yield of intermediate I or an acid addition salt thereof.
OBJECT AND SUMMARY OF THE INVENTION
The principle object of the present invention is to provide an improved process for preparing 3-amino-3-cyclobutylmethyl-2-hydroxypropionarnide of Intermediate I or an acid addition salt thereof. Another object of the present inv e a novel intermediate of formula E.
Formula E
P- Amiiie protecting group.
In one aspect, the present invention provides a process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide of Intermediate I or an acid addition salt thereof comprising the steps of:
a) reacting a benzophenone imine compound of formula A with a compound of formula B to give a compound of formula C,
Formula A Formnla B
Formula C
- alk l group ; L-Leaving group ;
b) protecting and hydrolyzing the compound of formula C to give compound of formula D,
Formula C Formula D
P-P btectin group
c) reacting compound of formula D with a morpholihe to give compound of formula
Formula D
Formula E
d) E to give compound of formula F,
e) reacting compound of formula F with a cyanohydrin compound to give compound of formula G,
f) ound of forrnula H , and
g) deprotecting compound of formula H and optionally isolating Intermediate I as its acid addition salt.
Formula H Intermediate I In another aspect, the Iriterniediate I is converted into Bbceprevir of formula I.
DETAILED DESCRIPTION 0F THE INVENTION:
The present invention provides an improved process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof of Intermediate I. It also provides a novel intermediate of formula E.
The schematic representation of "the present iriyention has given in scheme 4.
Formula C Formula D
Formula G
Formula E Formula F
Formula H Intermediate I
R- alkyl group ; L-Leaving group ; P-Protecting group
Scheitfe
As used herein, R- refers to an alkyl group straight or branched CI -9 alkyl, includes methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, s-butyl, t-butyl.
L refers to a leaving groups known in the art includes, halides, sulphoriate groups such as alkylsulphonates arylsulphonates.
P refers a protecting group known in the art includes Di t-Butyl dicarbamate (Boc), Benzyl carbamate, acetamide, trifluoroacetamide, phthalimide, benzylchloride, benzoylchloride, tritylamine, bertzylideneamine, tosylamide, methoxyethxoxymethyl, tetrahydropyaranyl (THP), and tertiary butyl.
Halide refers to F, CI, Br and I.
In one aspect, the present invention provides a process for preparing 3-amino-3- cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof of Intermediate I comp ising the steps of: a) A with compound of
b) to give a compound of
P-Protecting group
reacting the compound of formula D with a morpholine to give a compound of formula E,
ompound of formula F,
yanohydri compound to give a
Formula F
f) hydrolyzing compound of formula G to give compound of formula H,
Formula G
Formula H arid
g) deprotecting the compound of formula H arid optionally isolating Intermediate I as its acid addition salt
Formula H Intermediate I
R- alkyl group; L-Leaving group; P-Protecting group.
In one embodiment, a benzophenone imine compound of formula A is reacted with cyclobutyl methyl derivative of formula B to give amine compound of formula C in the presence of a suitable base and solvent. The suitable base is selected from metal hydroxide includes potassium hydroxide (KOH), sodium hydroxide (NaOH), metal carbonate includes sodium carbonate and potassium carbonate, preferably metal hydroxide potassium hydroxide; the suitable solvent is selected from polar aprotic solvent such as dimethyl sulfoxide ^ (DMSO), dimethylacetamide, tetrahydrofuran (THF), acetone, dimethyl formamide (DMF) and acetonitrile; preferably DMSO. The reaction between compound of formula A and cyclobutyl methyl derivative of formula B can optionally be carried out in presence of a phase transfer catalyst such as tetrabutyl ammonium bromide (TBAB) and crown ethers to give amine compound of formula C.
In US 6992220 and US 20050249702, the reaction of a benzophenone imine compound of formula A with cyclobutyl methyl halide of formula B is carried out in presence of potassium tertiary butoxide, wherein in the present invention said reaction is performed in presence of alkaline metal hydroxide such as KOH which results into cost effective and less time cycled.
In another embodiment, the amine compound of formula C is protected with protecting group P by treating with a protecting agent in a suitable solvent includes hexane, diethyl ether and methylene chloride (MDC), preferably methylene chloride. The protection can be carried out by following the procedures as described in Theodora W. Greene and Peter G. M. Wuts, "Protecting Groups In Organic Synthesis," third edition, John Wiley and Sons, New York. N.Y.
In another embodiment, the amine protected compound of formula C is hydrolysed to obtain formula D by treating with a base and suitable solvent, wherein the suitable base is selected from alkaline metal hydroxide, preferably NaOH in a suitable solvent selected from polar solvents such as methanol, ethanol, isopropyl alcohol (IP A) and propanol, arid butanol, preferably ethanol.
In one more embodiment, the acid compound of formula D is converted into a morpholine amide of formula E by treating formula D with a morpholine in presence of a suitable solvent and coupling agent. The suitable solvent includes methylene chloride (MDC), toluene, xylene and carbon tetrachloride (CC14), preferably methylene chloride. The suitable coupling agent includes l-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride (EDC.HC1), Ν,Ν'-Dicyclohexylcarbodiimide (DCC), 1,1*- Carbonyldiimidazole (CDI). The said reaction is optionally carried out in presence of an activator like 1-hydroxybenzotraizole. Compound of formula E can also be prepared by reacting alkylchloroformates such as ethylchloroformate, isobutylchloroformate with a compound of formula D followed by a morpholine. Alternatively compound of formula E can also be prepared directly from amino protected compound of formula C by reacting with a morpholine. In another embodiment of the present invention, formula E is also prepared by converting
In another embodiment, the morpholine amide compound of formula E is reduced into aldehyde compound of formula F by treating formula E with suitable reducing agent and suitable solvent, wherein the suitable reducing agent includes lithium aluminium hydride (LAH), diisobutylaluminum hydride (DIBAL-H) and sodium bis(2-methoxyethoxy) aluminumhydride (vitride). The suitable solvent includes ether solvents such as toluene, tetrahydrofuran (THF), diethyl ether.
In comparison with the prior art processes, the present invention provides a novel and simple process by replacing compound of formula J with the morpholine amide of formula E and further it is successfully established the reduction of compound of Formula J into corresponding aldehyde in process of preparing Intermediate I by employing commercially feasible reagent such as vitride solution instead of hazardous metallic hydride such as Lithium aluminium hydride.
In one more embodiment, the aldehyde compound of formula F is reacted with a cyanohydrin compound in presence of a suitable base and suitable solvent such as toluene, dichloromethane to obtain cyano compound of formula G. The cyanohydrin compound for the reaction is selected from ketone cyanohydrin, preferably acetone cyanohydrin. The base is selected from diisopropyl ethyl amine, dimethylamine, triethyl amine (TEA), trirnethyl amine, methylamine, ethanolamme, triphenylamine, pyridine and piperidine, preferably TEA. Yet in another embodiment, the cyanohydrin compound of formula G is hydrolyzed with a base in a suitable solvent such as DMSO and in presence H202 to obtain amide compound of formula H, wherein the base is selected from potassium carbonate, sodium carbonate, preferably potassium carbonate. In one embodiment, the cyanohydrin compound of formula G is converted into Intermediate I of ah acid addition salt thereof as per the process disclosed in US 20050249702 depicted in scheme 3,
In one embodiment, the amide compound of formula H is deprotected by treating with an acid in suitable solvent to give Intermediate I or an acid addition salt thereof The acid is selected from hydrochloric acid (HQ), hydrobromic acid (HBr), sulfuric acid (H2S04), trifluoro acetic acid (TFA), phosphoric acid (H3PO4), paratoluene sulfonic acid (pTSA) and the like, preferably HCl. The suitable solvent is selected from polar solvents such as methanol, ethanol, n-propanol, isopropyl alcohol (IPA) and butanol preferably IPA.
Yet another embodiment, the amide compound of formula H is converted into Intermediate I by the conventional methods.
In another aspect, present invention provides an improved process for preparing an aldehyde compound of formula F by reducing compound of formula J as represented in scheme 5.
Formula J
compound of formula J into aldehyde compound of formula F by substituting hazardous reducing agents like LAH with vitride solution to offer a commercially viable process.
According to the present invention, the reduction of the compound of formula J into compound of formula F is carried out by treating compound of formula J with sodium bis(2-methoxyethoxy)alumirtumhydride (Vitride) in a suitable solvent selected from polar aprotic solvent includes, tetrahydrofurari (THF); preferably THF.
In another aspect, the present invention provides novel intermediate of formula E.
Formula E
P- Amide protecting group. In one embodiment, the novel morphoiine compound of formula E is converted into Boceprevir of formula I.
In one more embodiment, the aldehyde compound of formula J is further converted into Boceprevir by the conventional methods.
in another embodiment, the Intermediate I is converted into Boceprevir of formula I as per the process disclosed in US 7012066, US 20050249702, WO 2008079216 and WO2002008244.
The following non-limiting examples illustrate specific embodiments of the present invention. The examples are not intended to be limiting the scope of present inventio in any way.
Examples:
129.8 g of Benzophenone, 50 g of glycine ethyl ester hydrochloride (0.5 moles), 3.38 g of 7-t0luenestilf0nic acid (0.05 moles) and 205 ml toluene were taken in to BF equipped with dean-stark apparatus. To the reaction mixture was added 96.59 g of N,N- diisopropyl ethyl amine and was heated to 1 10-1 19 °C and maintained at same temperature with stirring for six hours. During the reaction, water was removed from the reaction azeotropically. After completion of the reaction, the reaction mixture was cooled to 20 °C and the reaction- mixture was washed with water and layers were separated. The organic layer was concentrated under reduced pressure to get the product as an oily residue (169 g).
Example -2: Preparation of formula C (R = ethyl)
(N-diphenylmethylene)glycine ethyl ester (17.9 g, Example 1) was dissolved in 50 ml of DMSO and cooled to 0 °C. To this 11.27 g of potassium hydroxide was added and stirred for 10 min. To the reaction mixture 10 g of Cyclobutyl methyl bromide (Formula B-Leaving group is halide, preferably Br) was added at 0 °C and continued stirring for one hour at 0 °C. After completion of the reaction, toluene was added to the reaction mass and filtered through Hyflo bed. Water was added to the filtrate and extracted with toluene. The organic layers were combined and washed with brine solution; dried over anhydrous Na2S04 and concentrated under reduced pressure to get oily residue. The resulting oily residue was dissolved in diisopropyl ether and added 50% aqueous HCl solution. The reaction mass was maintained at room temperature with stirring for 3 hours. Separated the aqueous layer from reaction mass and neutralized with aqueous sodium carbonate solution. Extracted the product with dichloromethane and concentrated under reduced pressure to get product as an oily mass (7 g). Example-3: Pre
Formula C Formula D
To a solution of amine (7 g, Example-2) in 70 ml of dichloromethane, 9.39 g of ditert-butyl dicarbonate was added at 0 °C. The reaction mixture was stirred for 12 hrs at room temperature. After completion of the reaction, reaction mixture was concentrated under reduced pressure to get an oily residue. The oily residue was dissolved in 10 ml of rnethanol/ethanol and treated with sodium hydroxide solution (3g in 20 ml of water) and stirred for 3 hrs at room temperature. After completion of reaction, reaction mass was concentrated under reduced pressure and water was added and stirred for 10 min. The reaction mixture was cooled to 10-15 °C and pH was adjusted to 1-2 by using IN HCl solution. The product was extracted with dichloromethane. The combined organic layers were dried over Na S04 and concentrated under reduced pressure to get the product as an oily mass (8 g).
Example-4: Preparation of formula E (P
Formula D Formula E
To a solution of BOC-acid (8 g, example-3) in 80 ml of dichloromethane, 5.18 g of 1-Hydroxybenzotraizole and 10 ml of morpholine were added under nitrogen atmosphere. To the above reaction mixture 7.56 g of l-ethyl-3-(3- dimethylaminopropyl)carbodiimide) hydrochloride (EDC.HCl) was added and stirred for 4 hrs. After completion of reaction, reaction mixture was filtered and washed with dichloromethane. The filtrate was washed with 10% aqueous HC1 solution and separated the organic layer. The organic layer was washed with 5% sodium bicarbonate solution followed by brine solution. The organic layer was dried over Na2S04 and concentrated under reduced pressure to obtain 6 g product as solid.
Example-5: Preparation of formula E (P = Boc):
To a solution of BOC-acid (10 g, example-3) in 100 ml of dichloromethane was added Triethylamine (13.74 gm) at -15 °C. Then added 5.95 gm of Pivaloyl chloride and stirred for one hour at -15 °C under nitrogen atmosphere. 4.47 gm of Morpholine was added to the above reaction mass at -15 °C and stirred for one hour. After completion of reaction, water was added and separated the layers. Organic layer washed with 10% aqueous HC1 solution followed by 5% Sodium bicarbonate solution. Finally washed the organic layer with brine solution and dried over Na2S0 . Concentrated the organic layer under reduced pressure and recrystallized using hexane/heptane to get 11 gm product as white solid.
Example -6: Preparation of formula F (P
to get the product as an oily mass (2.4 g).
Exampie-7:
Formula J
To a solution of 5 g of BOC-acid (Example-3) in 100 ml of dichloromethane, 3.3 g of l-HydrOxybenzotraizole, 9.1 1 ml of diisopropyl ethyl amine and 3 g of Ν,Ο- dimethylhydroxylamine hydrochloride were added under nitrogen atmosphere. To the reaction mixture 4.72 g of EDC.HC1 was added and stirred for 12 hrs. After completion of reaction, 100 ml of 20% aqueous HC1 solution was added, stirred and the layers were separated. Aqueous layer was extracted with dichloromethane and the organic layers were combined arid were washed with saturated sodium bicarbonate solution, followed by brine solution. The organic layer was dried over Na2SG4 and concentrated under reduced pressure to get 5 g of product as white solid.
Example-8: Preparation of formula F (P
Formula J
2 g of solution of compound of formula J (Example-6) in 20 ml of tetrahydrofuran was cooled to 0 °C and vitride solution (6.05 ml, 70% solution in toluene) was added drop wise. The reaction mixture was slowly heated to room temperature and stirred for 3 hours. After completio of. reaction, the reaction mixture was cooled to 0-5 °C and quenched with ice water followed by 10% aqueous HCI solution. Then, to the reaction mixture dichlGroniethane was added and filtered through hyflow bed and Washed with dichloromethane. The layers were separated and aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine solution, dried over Na2S04 and concentrated under reduced pressure to get the product as an oily mass (1.5 g). Exampl-9: Preparation of formula G (P = Boc)
Formula G
Formula F
To the 1 g solution of BOC-aldehyde (formula F- P is Boc) in 10 ml of toluene 1.5 g of acetone cyanohydrin and triethylamine (1.22 ml) were added and stirred for 24 h at room temperature. After completion of the reaction, 20 ml of 10% aqueous HCI solution were added and stirred. The layers were separated and the aqueous layer was extracted with toluene and organic layers Were combined. The combined organic layers were washed with water followed by brine solution, dried over Na2S0 and concentrated under reduced pressure to get the product as an oily mass (1 g).
Example-10: Preparation of formula H (P
Formula G Formul H
To the 1 g solution of BOC-cyano alcohol (Example-8) in 5 ml of DMSO 0.5 g of potassium carbonate was added and heated to 40-45 °C. To the reaction mixture 2 ml of 35% H202 solution was added drop wise over one hour and stirred at same temperature for 4 h. After completion of the reaction 15 ml of water was added and cooled to 0 °C and continued stirring for 5 h at same temperature. The reaction mixture was filtered. The obtained solid was washed with water and dried at 50-55 °C for 6 h give 0.4 g of product.
Example 11: Preparation of Intermediate I.
Formula H Intermediate I
To the 0.5 g solution of BOC-hydroxy amide (Example-9) in 3 ml isopropyl alcohol IPA.HC1 solution (2 mi, 9% w/w) was added. The reaction mass temperature was heated to 40-45 °C and continued stirring for 6 hours. The reaction mass temperature was cooled to 0-5 .°C and stirred for one hour. Filtered the obtained solid and dried at '■ 6.0-65 °C for 6 hours to give 0.3 g of compound.
Claims
1. A process for preparing intermediate compound of formula I comprising the steps of :
Intermediate I
a) reducin a com ound of formula E to give a compound of formula F,
Formula E Formula F
b) reacting the compound of formula F with a cyanohydrin compound to give a compound of formula G,
Formula G
Formula F
c) e a compound of formula H,
Fo™ula G ' Formula H and
d) deprotecting the compound of formula H and optionally isolating Intermediate
Formula H Intermediate I
R- alkyl group; L-Leaving group; P-Protecting group.
2. The process according to the claim 1, wherein the reducing step is carried out with a reducing agent selected from lithium aluminium hydride (LAH), diisohutylalurninum hydride (DIBAL-H) and sodium bis(2-methoxyethoxy) aluminumhydride (vitride).
3. TM'- ri>cesg ',aei¾idftig to the claim 1, wherein the compound of formula F is reacted with cyanohydrin in presence of a base arid a solvent.
4. The process according to the claim 3, wherein the suitable base is selected from diisopropyl ethyl amine, dimethylamine, triethyl amine (TEA), trimethyl amine, methylamine, ethanolarriine, triphenylamine, pyridine and piperidine and the like.
5. The process according to the claim 1, wherein the compound of formula G is hydro lyzed in presence of a base.
6. The process according to the claim 5, wherein the base is selected from potassium carbonate, sodiurh carbonate arid the like.
7. The process according to the claim 1, wherein the compound of formula H is optionally deprotected by treating with an acid arid a suitable solvent.
8. The process according to the claim 7, wherein the suitable acid is selected from hydrochloric acid HC1), hydrobrOrnic acid (HBr), sulfuric acid (H S04), trifluoro acetic acid (TFA), phosphoric acid (H3P04), paratoluene sulfonic acid (pTSA) and the like.
9. The process according to the claim 1 , wherein the compound of formula E is prepared comprising the steps of : a) reacting a benzophenone imine compound of formula A with compound of formula B to give compound of formula C,
Formula A Formula B
Formula C
R- alkyl group ; L-Leaving group ;
Formula C Formula D
P-Protecting group
c) reacting the compound of formula D with a morpholine to give the compound of formula E,
Formula D
Formula E
P-Protecting group
10. A process for preparing compound of formula F comprising reducing formula J with sodium bis(2-methoxyethoxy)aluminumhydride (Vitride) in a suitable solvent.
Formula F
Formula J
R- alkyl group; P-protecxtlng group
11. The process according to the claim 10, wherein the suitable solvent is tetrahydfofuran.
Formula E
P-Protecting group
13. The use of compound of claim 12, in the preparation of Intermediate I.
14. The use of compound of claim 12, in the preparation of Boceprevir.
15. The process according to the proceeding claims, wherein the compound of formula I is further converted into Boceprevir.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4980/CHE/2012 | 2012-11-29 | ||
IN4980CH2012 | 2012-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014083575A2 true WO2014083575A2 (en) | 2014-06-05 |
WO2014083575A3 WO2014083575A3 (en) | 2016-06-02 |
Family
ID=49956289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2013/000697 WO2014083575A2 (en) | 2012-11-29 | 2013-11-14 | Improved process for the preparation of boceprevir intermediate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014083575A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104744291A (en) * | 2015-02-13 | 2015-07-01 | 宁波九胜创新医药科技有限公司 | N-benzyl-4-cyclobutyl-2-hydroxy-3-nitrobutyrylamide and use thereof |
CN112094204A (en) * | 2019-06-18 | 2020-12-18 | 成都郑源生化科技有限公司 | Method for preparing Fmoc-Tyr (tBu) -OH |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002008244A2 (en) | 2000-07-21 | 2002-01-31 | Schering Corporation | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
US20050249702A1 (en) | 2004-05-06 | 2005-11-10 | Schering Corporation | (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease |
US6992220B2 (en) | 2003-06-17 | 2006-01-31 | Schering Corporation | Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof |
WO2008079216A1 (en) | 2006-12-20 | 2008-07-03 | Schering Corporation | Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
US20110034705A1 (en) | 2007-12-21 | 2011-02-10 | Schering-Plough Corporation | Process For the Synthesis of 3- Amino-3-Cyclobuthylmethyl-2-Hydroxypropionamide or Salts Thereof |
-
2013
- 2013-11-14 WO PCT/IN2013/000697 patent/WO2014083575A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002008244A2 (en) | 2000-07-21 | 2002-01-31 | Schering Corporation | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
US7012066B2 (en) | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US6992220B2 (en) | 2003-06-17 | 2006-01-31 | Schering Corporation | Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof |
US20050249702A1 (en) | 2004-05-06 | 2005-11-10 | Schering Corporation | (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease |
WO2008079216A1 (en) | 2006-12-20 | 2008-07-03 | Schering Corporation | Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
US20110034705A1 (en) | 2007-12-21 | 2011-02-10 | Schering-Plough Corporation | Process For the Synthesis of 3- Amino-3-Cyclobuthylmethyl-2-Hydroxypropionamide or Salts Thereof |
Non-Patent Citations (1)
Title |
---|
THEODORA W. GREENE; PETER G. M. WUTS: "Protecting Groups In Organic Synthesis", JOHN WILEY AND SONS |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104744291A (en) * | 2015-02-13 | 2015-07-01 | 宁波九胜创新医药科技有限公司 | N-benzyl-4-cyclobutyl-2-hydroxy-3-nitrobutyrylamide and use thereof |
CN112094204A (en) * | 2019-06-18 | 2020-12-18 | 成都郑源生化科技有限公司 | Method for preparing Fmoc-Tyr (tBu) -OH |
CN112094204B (en) * | 2019-06-18 | 2022-06-21 | 成都郑源生化科技有限公司 | Method for preparing Fmoc-Tyr (tBu) -OH |
Also Published As
Publication number | Publication date |
---|---|
WO2014083575A3 (en) | 2016-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8604241B2 (en) | Method for synthesis of (1S, 2R)-milnacipran | |
US20090143472A1 (en) | Intermediate compounds and their use in preparation of lacosamide | |
KR20120128667A (en) | A process for the preparation of lacosamide | |
KR101036536B1 (en) | Synthesis of (S)-(+)-3- (aminomethyl) -5-methyl hexanoic acid | |
KR102122569B1 (en) | Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine | |
WO2014125506A2 (en) | A process for the preparation of ivacaftor and its intermediates | |
WO2014152752A1 (en) | Methods for the synthesis of chiral kynurenine compounds | |
TW201806927A (en) | Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides | |
WO2016024284A2 (en) | A process for the preparation of mirabegron and its intermediates | |
CN115515957A (en) | Stereoselective Synthesis of Intermediates for the Preparation of Heterocyclic Compounds | |
WO2014083575A2 (en) | Improved process for the preparation of boceprevir intermediate | |
WO2013066734A1 (en) | Process and intermediates for the preparation of 3-amino-4-cyclobutyl-2-hydroxybutanamide and salts thereof | |
WO2022241188A1 (en) | Enantioselective synthesis of aminotropane compound | |
ZA200502275B (en) | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | |
WO2011156355A1 (en) | Production method of phenyl guanidine salts and their intermediates | |
US8957252B2 (en) | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | |
JP5374895B2 (en) | Process for producing optically active fluoroamines | |
JP2010090031A (en) | Method of producing bicyclic proline compound | |
CN103249306A (en) | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium | |
JP6781030B2 (en) | L-carnosine derivative or salt thereof, and method for producing L-carnosine or salt thereof | |
US10329325B2 (en) | Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide | |
RU2362766C2 (en) | Method of obtaining benzylamine derivative and acylbenzylamine derivative | |
US20120101301A1 (en) | Process for preparing carboxylic acid amides useful in the treatment of muscular disorders | |
US9718765B1 (en) | Process for preparation of optically pure N-substituted-3-methoxypropionic acid derivatives | |
WO2007029267A1 (en) | Process for industrially viable preparation of imidapril hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13821192 Country of ref document: EP Kind code of ref document: A2 |